One of the threads about the RS mentions "healing of HPV"
Human Papilloma Virus (HPV) never really heals. It becomes an epivirus that hides inside cells and is clinically silent. It can breakout and re-infect under conditions of stress at any time during an infected person's lifetime and cause warts or cancers. Hence the strong medical interest in a vaccine which would prevent the initial infection and (possibly) be used to re-fortify the immune system from time to time to prevent or treat (cause it to become subclinical again) the infection. In any case, investors who want to know more about this can go to the CDC website and look at the information published by the Division of High-Consequence Pathogens and Pathology (DHCPP). This group is looking at emerging diseases all over the world, along with WHO (World Health Organization).
But Inovio's place here is assured for lots of different reasons that have to do with their science and technology.
PS - I think the RS would place the stock in the optimum range for Mid to Large Cap companies which is above $30. Been there with BAX, CRL, GEN and others. Bought INO because of its potential to be successful in 3 years. That was following the dilution last year.
You have to look at it this way . . . how many times in a lifetime does a person get revaccinated for tetanus? Or (before it was eradicated from the Earth) small pox? This type of vaccination and revaccination will become common place for women who also have mammograms. Or men who have multiple sexual partners. That is the importance of a vaccine for HPV.